Get started

Stockstobuy

Wave V of 3 in INDIGOThe airline company is seen trying to begin the wave iii of V of 3 in an attempt to go past previous ATH and then towards the 3K mark. It should also be noted that Indian airlines will operate a total of 23,732 flights every week during the winter schedule( approved by the Directorate General of Civil Aviation (DGCA). As per the new order, the said number of departures is an 8 per cent rise in the number of flights compared to a year ago period. Since indigo is the largest Indian passenger carrier it will benefit from this upbeat schedule. It presents a good trading set up with excellent RR SL- 2390 TGT- 2790
NSE:INDIGOLong
by neeraj_2_sharma
TRADE SETUP_ 10% upside for COROMANDELThis specialty chemical stock is seen in a beautiful Elliot wave structure since the Jan 2023 and has outperformed not only its peers but also major Indian Indices. The stock recently had a steep and swift decline in October. This very declined was in fact the wave iv of wave 3 and now the stock has kicked off in the Wave v of Wave 3 structure. It would be wise to wait for a small dip in the stock(towards 1070-1080) to make an entry and ride next wave up towards the 1215 zone. Note*- Please do own your own research and analysis before taking up any financial positions.
NSE:COROMANDELLong
by neeraj_2_sharma
ULTRATECH CEMENT- PATHWAY TO 12K AS PER WEEKLY WAVE COUNTSThe largest and most prosperous cement company of India- Ultratech Cement is expected to have more upside of 30-40% from current levels as the weekly wave counts suggest. To put it in very simple words without using too much of Elliot wave jargon, the next leg up is unfolding now which can be projected going somewhere closer to 9200.(the current wave structure technically should be labeled as 1-2-I-II-i-ii-iii-iv-v, which is simply read as Wave v of Wave III of Wave 3). The inner rising channel boundaries can be used as a pathway until the bigger wave 3 does not complete. I hope the chart is self explanatory and would not require too much of decoding as to what i am trying to convey. Note*- this is not a buy/sell recommendation. this post is for educational purpose only.
NSE:ULTRACEMCOLong
by neeraj_2_sharma
Good-Buy STOCKS: HOODHi Traders, Investors and Speculators of Charts📈📉 After losing nearly 90% of it's high, NASDAQ:HOOD is currently trading close to all-time lows. This could make for a great buy and hold opportunity, whilst some patience may be needed to wait for ideal target zones. Higher lows are observed after bottoming out at $6, indicating that the bottom is most likely in for HOOD. In other words a spot entry here has a really low risk and high reward setup. _______________________ 📢Follow us here on TradingView for daily updates and trade ideas on crypto , stocks and commodities 💎Hit like & Follow 👍 We thank you for your support ! CryptoCheck NASDAQ:HOOD
NASDAQ:HOODLong
by Crypto-Check-
9
SRPT Sarepta Therapeutics Potential Buyout SoonIf you haven`t bought SRPT here: Then you need to know that there is a Massive catalyst coming! Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November. This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17. Some even bought the $210 strike price! They also have a big partnership with the giant Roche Holding AG (RHHBY). I think SRPT Sarepta Therapeutics is well positioned for a potential takeover soon! Looking forward to read your opinion about it.
NASDAQ:SRPTLong
by TopgOptions
ACRS Aclaris Therapeutics Potential BuyoutACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025. ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023. ACRS reached 52 week low today: $5.05. Analysts Price Targets: $21 The Goldman Sachs Group $29 BTIG Research $38 Cantor Fitzgerald $43 HC Wainwright Considering the above, I think ACRS might be an easy +3X! Looking forward to read your opinion about it.
NASDAQ:ACRSLong
by TopgOptions
3
Naga Dhunseri Mid Term Idea with an RR of 1:5, 50% + ROI1) The stock is poised for a multiyear breakout, it has formed an ascending triangle pattern in monthly timeframe indicating a strong up move once after the ATH is broken. 2) Candlesticks show extremely bullish price action. Inside bars in Monthly as well. 3) RSI in monthly and weekly are supportive, moving up after a small correction. For a swing trade - One can enter at the demand 1 level if there is a reversal in hourly / 75 min time frame and look for Target 1 and Target 2 zones as targets. 10% up move. For a mid term trade - One can look to enter at the same demand zone as swing, or once after the ATH is sold off at first and then at a further upside reversal, precisely after a dip and bounce back in Daily timeframe RSI as currently it is inching 90+. As per risk management. For the Mid term, SL can be at 1500. Targets at 3100. Wish you all profits and happy trading!
NSE:NDGLLong
by Rugminik
1
NVAX Novavax Vaccine approved! Buy Opportunity!If you haven`t bought NVAX during the pandemic: Then you need to know that NVAX Novavax's recent achievements in gaining full marketing authorization for its COVID-19 vaccine, Nuvaxovid, in the UK and Singapore, alongside its availability in major U.S. pharmacies, have ignited optimism among investors. These milestones signify a bright future for NVAT stock. The international authorization of Nuvaxovid opens doors to vast markets, enhancing revenue potential and global recognition for Novavax. the EU delayed the approval, but will update its decision by the end of this month. Nuvaxovid's availability at CVS and Rite Aid in the U.S. immediately after regulatory clearance demonstrates its acceptance and accessibility. Nuvaxovid is a protein-based COVID-19 vaccine, different from the mRNA vaccines of PFE and MRNA. My price target is $10 by the end of this month. Looking forward to read your opinion about it.
NASDAQ:NVAXLong
by TopgOptions